Belgian hadron therapy consortium: what changed
Belgian hadron therapy consortium
Largest movements
No asset line moved by more than 1% of the balance sheet total.
No liability line moved by more than 1% of the balance sheet total.
- Gross operating margin +€2,401
up €2,401 (+67.7%), from -€3,545 to -€1,144
- Purchases and services -€2,201
down €2,201 (-65.8%), from €3,345 to €1,144
- Financial income +€513
up €513 (+159%), from €322 to €835
- Financial charges +€197
up €197 (+197%), from €100 to €297
Change in the result, 2023 to 2024
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2023 and 2024 balance sheets and the 2024 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2023 | 2024 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €79,523 | €78,917 | -€606 | -0.8% |
| Current assets | 29/58 | €79,523 | €78,917 | -€606 | -0.8% |
| Cash at bank and in hand | 54/58 | €79,523 | €78,917 | -€606 | -0.8% |
| Total equity and liabilities | 10/49 | €79,523 | €78,917 | -€606 | -0.8% |
| Equity | 10/15 | €64,255 | €63,649 | -€606 | -0.9% |
| Profit (loss) carried forward | 14 | €64,255 | €63,649 | -€606 | -0.9% |
| Amounts payable | 17/49 | €15,268 | €15,268 | = | 0.0% |
| Accrued charges and deferred income | 492/3 | €15,268 | €15,268 | = | 0.0% |
| Goods, raw materials, services and sundry goods | 60/61 | €3,345 | €1,144 | -€2,201 | -65.8% |
| Gross operating margin | 9900 | -€3,545 | -€1,144 | +€2,401 | +67.7% |
| Operating profit (loss) | 9901 | -€3,545 | -€1,144 | +€2,401 | +67.7% |
| Financial income | 75/76B | €322 | €835 | +€513 | +159% |
| Recurring financial income | 75 | €322 | €835 | +€513 | +159% |
| Financial charges | 65/66B | €100 | €297 | +€197 | +197% |
| Recurring financial charges | 65 | €100 | €297 | +€197 | +197% |
| Profit (loss) for the period before taxes | 9903 | -€3,323 | -€606 | +€2,717 | +81.8% |
| Profit (loss) for the period | 9904 | -€3,323 | -€606 | +€2,717 | +81.8% |
| Profit (loss) for the period to be appropriated | 9905 | -€3,323 | -€606 | +€2,717 | +81.8% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2023 and 31 December 2024. Green is a favourable move for that line, red an unfavourable one. Prepared on 7 November 2026 via checked.be.